Written and edited by Yianni Kiromitis. Published 9 October 2026. Sources checked 8 October 2026. Clinical review pending.
Semaglutide improved some blood-based markers of ageing in a small study of adults with HIV and excess abdominal fat. One measure suggested a 9% slower pace of ageing than placebo. This is a promising signal, but it does not show that people lived longer or became younger. [1]
The result comes from Michael Corley and colleagues’ 2026 paper in Nature Communications. The paper was published on 19 May; the University of California reported it on 11 June. For the wider evidence on the compound, see the semaglutide evidence profile. [1] [2]
Who took part in the study?
The ageing analysis included 84 adults with HIV-associated lipohypertrophy: excess fat build-up, particularly around the abdomen. There were 45 people in the semaglutide group and 39 in the placebo group. Researchers compared blood samples taken at the start and after 32 weeks. [1]
The original trial enrolled 108 people. That larger number describes everyone randomly assigned to treatment, not everyone included in the ageing analysis. This distinction matters when judging how much evidence supports the headline. [1]
The trial was randomised and double-blind. Treatment was assigned by chance, and participants and research staff did not know who received the drug or placebo. This strengthens the comparison. However, the original trial studied changes in body fat. The ageing analysis was added afterwards, rather than being a planned main outcome. [1]
What does “9% slower ageing” actually mean?
The figure refers to DunedinPACE, a tool that estimates the pace of ageing from chemical marks on DNA. Those marks are called DNA methylation. They help regulate gene activity without changing the DNA sequence. An “epigenetic clock” uses patterns in these marks to estimate an aspect of biological ageing. [1]
After allowing for differences between the groups, the semaglutide group had a DunedinPACE score 0.09 units lower than the placebo group. The authors describe this as approximately 9% slower ageing. The 95% confidence interval, which shows the uncertainty around that estimate, was −0.17 to −0.02 units. These are estimates from an ageing marker, not measurements of extra years of life. [1]
The result does not mean each participant became 9% younger. Nor does it establish that someone taking the drug will live 9% longer. To answer those questions, researchers would need to track health outcomes over a much longer period. [1]
What does the headline leave out?
The main omissions concern how the analysis was designed and what its measurements can establish. The findings deserve follow-up, but the evidence is less settled than a simple claim that semaglutide “slows ageing”. [1]
| Finding or headline | What it can support | What it cannot establish |
|---|---|---|
| “9% slower ageing” | A difference in a blood-based pace-of-ageing score. | 9% longer life or 9% rejuvenation. |
| Improved brain or heart ageing measures | Changes in scores calculated from blood DNA markers. | Direct evidence that brain or heart tissue became younger. |
| Results from a randomised trial | A stronger treatment comparison than an uncontrolled observation. | A prospectively designed longevity trial. |
| Several positive clock results | A pattern that merits further testing. | Agreement across all clocks or confirmed clinical benefit. |
Table: interpretation of Corley et al. (2026), Results, figure legends and Discussion. [1]
The team ran many tests but did not adjust the results to account for this. This is known as a lack of adjustment for multiple comparisons. When many tests are run, there are more chances of obtaining a positive result by chance. This does not make the findings worthless. It means they should be treated as exploratory and checked in a new trial with outcomes set in advance. [1]
Not every clock showed a clear effect. Some clocks designed to measure resilience or possible causes of ageing showed no clear change. The paper also states that the organ-specific scores came from blood samples. They were not direct tests of ageing within those organs. [1]
Could the effects be related to loss of body fat?
Yes. The authors discuss reduced abdominal fat, improved metabolic health and changes in inflammation as possible explanations. The study does not establish a separate anti-ageing action independent of these changes. [1]
This matters because the participants had a specific metabolic condition. A marker may improve as that condition improves. The same result cannot simply be assumed in people without HIV, people at a healthy weight or people seeking longer life without a treatment need. [1]
Does this change the evidence for peptide longevity claims?
It adds human evidence about semaglutide and particular ageing markers. It does not establish lifespan extension, and it cannot be applied to other compounds just because they are also described as peptides. The tested drug, population and outcome all matter. [1]
The useful distinction is between a change in a marker and a benefit that a person experiences, such as more years in good health. Those claims need different evidence. The site’s review of peptide longevity claims covers the broader question; this study addresses one narrower part of it.
What would make the evidence stronger?
A larger trial would need to plan its ageing outcomes before treatment begins, account for multiple testing and follow participants for longer. It should also test whether changes in clock scores correspond to meaningful improvements in health. The authors themselves call for replication in larger and more diverse groups. [1]
It would be useful for a separate team to repeat the study. Corley reported an advisory role with TruDiagnostic, and two co-authors reported that they worked there. These relationships do not disprove the findings, but they belong alongside the results when readers assess the evidence. [1]
The study shows changes in several ageing markers in this group of adults. Whether those changes predict longer or healthier lives remains unanswered. Explore the peptide evidence library and how evidence is rated for the distinction between a measured finding and a broader claim.
Common questions
Did semaglutide reverse ageing?
No. This analysis found changes in some DNA-based ageing markers over 32 weeks. Such scores are statistical estimates, not proof that ageing has reversed. The findings do not establish that participants became younger, lived longer or gained more years free of disease. [1]
Was the study conducted in healthy adults?
No. It involved adults with HIV-associated lipohypertrophy, a condition involving excess fat accumulation. This is a specific population with its own health context. The results cannot establish whether people without HIV, or those without excess body fat, would show the same response. [1]
Why do reports mention both 108 and 84 participants?
The original trial randomly assigned 108 people to semaglutide or placebo. The later ageing analysis used paired blood samples from 84 participants: 45 in the drug group and 39 in the placebo group. The smaller number is the relevant sample size for the ageing findings. [1]
Does this prove that other peptides slow ageing?
No. The analysis tested semaglutide in one population using specific ageing measures. It did not test other peptide products. A result for one compound cannot establish the effects of another, and changes in ageing markers do not by themselves prove that any product extends life. [1]
Does the study establish an anti-ageing treatment?
No. It provides a reason for further research, rather than a proven treatment for extending life. The analysis was exploratory, follow-up was short and clinical longevity outcomes were not established. It cannot determine whether starting treatment solely for ageing would provide more benefit than harm. [1]
References
1. Corley MJ, Dwaraka VB, Pang APS, et al. (2026). Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nature Communications 17, 6606. DOI: 10.1038/s41467-026-72861-3. Findings used: sample sizes, trial design, DunedinPACE estimate, multiple-testing methods, null results, limitations and disclosures. Accessed 8 October 2026. This analysis paraphrases and interprets the paper; it is not endorsed by its authors. The paper is licensed under CC BY 4.0.
2. Bard SC. New study shows popular GLP-1 weight loss drug may slow biological aging. University of California, 11 June 2026. Used for the news context and report date.